Last reviewed · How we verify

Hepatitis A Pediatric Vaccine

Sanofi Pasteur, a Sanofi Company · Phase 3 active Biologic

This vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protection against infection.

This vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protection against infection. Used for Prevention of hepatitis A infection in pediatric patients.

At a glance

Generic nameHepatitis A Pediatric Vaccine
SponsorSanofi Pasteur, a Sanofi Company
Drug classInactivated viral vaccine
TargetHepatitis A virus antigen
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

Hepatitis A pediatric vaccines contain inactivated hepatitis A virus antigen that triggers both humoral and cellular immune responses. Upon vaccination, the immune system develops antibodies (primarily IgG) that neutralize the virus and provide long-term protection against hepatitis A infection. The vaccine is formulated specifically for pediatric dosing and administration schedules.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: